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ABSTRACT
Objective Hydrothermal duodenal mucosal resurfacing 
(DMR) is a safe, outpatient endoscopic procedure. 
REVITA-2, a double- blind, superiority randomised 
controlled trial, investigates safety and efficacy of DMR 
using the single catheter Revita system (Revita DMR 
(catheter and system)), on glycaemic control and liver fat 
content in type 2 diabetes (T2D).
Design Eligible patients (haemoglobin A1c (HbA1c) 
59–86 mmol/mol, body mass index≥24 and ≤40 kg/
m2, fasting insulin >48.6 pmol/L, ≥1 oral antidiabetic 
medication) enrolled in Europe and Brazil. Primary 
endpoints were safety, change from baseline in HbA1c 
at 24 weeks, and liver MRI proton- density fat fraction 
(MRI- PDFF) at 12 weeks.
Results Overall mITT (DMR n=56; sham n=52), 
24 weeks post DMR, median (IQR) HbA1c change was 
−10.4 (18.6) mmol/mol in DMR group versus −7.1 
(16.4) mmol/mol in sham group (p=0.147). In patients 
with baseline liver MRI- PDFF >5% (DMR n=48; sham 
n=43), 12- week post- DMR liver- fat change was −5.4 
(5.6)% in DMR group versus −2.9 (6.2)% in sham group 
(p=0.096). Results from prespecified interaction testing 
and clinical parameter assessment showed heterogeneity 
between European (DMR n=39; sham n=37) and 
Brazilian (DMR n=17; sham n=16) populations 
(p=0.063); therefore, results were stratified by region. In 
European mITT, 24 weeks post DMR, median (IQR) HbA1c 
change was –6.6 mmol/mol (17.5 mmol/mol) versus 
–3.3 mmol/mol (10.9 mmol/mol) post- sham (p=0.033); 
12- week post- DMR liver- fat change was –5.4% (6.1%) 
versus –2.2% (4.3%) post- sham (p=0.035). Brazilian 
mITT results trended towards DMR benefit in HbA1c, but 
not liver fat, in context of a large sham effect. In overall 
PP, patients with high baseline fasting plasma glucose 
((FPG)≥10 mmol/L) had significantly greater reductions in 
HbA1c post- DMR versus sham (p=0.002). Most adverse 
events were mild and transient.
Conclusions DMR is safe and exerts beneficial disease- 
modifying metabolic effects in T2D with or without 
non- alcoholic liver disease, particularly in patients with 
high FPG.
Trial registration number NCT02879383
INTRODUCTION
The global prevalence of type 2 diabetes mellitus 
(T2D) and non- alcoholic fatty liver disease, due in 
part to the widespread adoption of diets with high 
sugar and fat content, is increasing at an alarming 
rate.1–3 Insulin resistance (IR) and hyperinsulinemia 
play an important role in the pathological progres-
sion and decompensation of multiple organ systems 
in these conditions.3 4 Despite the fact that over 
50 unique pharmacological agents are currently 
approved to treat T2D, and the benefits of dietary 
interventions are well established, most patients 
with T2D are unable to sustain adequate glycaemic 
control (recommended haemoglobin A1c (HbA1c) 
levels≤53 mmol/mol).5 6 Poor adherence and 
persistence to prescribed therapies, drug- to- drug 
interactions, side effects, and patient dissatisfaction 
are fundamental barriers to the real- world effective-
ness of current approaches to manage T2D.7 8
Bariatric/metabolic surgeries that bypass nutrient 
contact from the duodenum, such as Roux- en- Y 
gastric bypass and biliopancreatic diversion, orig-
inally intended to aid weight loss, have demon-
strated compelling evidence to provide sustainable 
improvements in patients with T2D.9–11  Bariatric/
metabolic surgery is safe with a low mortality 
rate (0.1%–0.5%), similar to that observed after 
cholecystectomy or hysterectomy.12 Nevertheless, 
only 1% of eligible patients undergo this type of 
surgery.13 14 Endoscopic procedures are emerging 
as an effective and minimally invasive approach to 
treat obesity and/or T2D, closing the gap between 
pharmacological  therapy  and  bariatric/metabolic 
surgery.
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Duodenal mucosal resurfacing (DMR) is a minimally inva-
sive endoscopic procedure performing circumferential mucosal 
lift and hydrothermal ablation of the duodenal mucosa.15 The 
first- in- human safety trial showed that DMR is safe and able to 
improve glycaemic control in proportion to the length of the 
ablated duodenal mucosal segment.16 17 The following multi-
centre, open- label REVITA-1 trial in 46 patients with poorly 
controlled T2D showed a significant reduction of baseline HbA1c 
at 24 weeks after DMR of −10±2 mmol/mol  (−0.9%±0.2%; 
p<0.001).18
Herein, we report the results of the first double- blind, multi-
centre, randomised controlled trial with a single DMR proce-
dure, which assessed the efficacy and safety of DMR in patients 
with T2D with or without NAFLD versus a sham endoscopic 
procedure.
METHODS
Additional protocols and complete procedures are described in 
the online supplemental material and methods section.
Trial design and oversight
REVITA-2 was a randomised, double- blind (patient and endo-
crinologist), sham- controlled trial conducted across 11 sites 
(nine in Europe (Italy, UK, Belgium and Netherlands) and two in 
Brazil) from 11 September 2017 to 15 December 2018 (online 
supplemental figure 1).
A data monitoring committee oversaw this study (see online 
supplemental methods for details).
Randomisation and masking
Patients (see online supplemental table 1 for complete eligi-
bility criteria) were randomised (1:1) to undergo the DMR or 
sham procedure by using a central web- based random allocation 
system (see online supplemental methods for details). Endocri-
nologists and patients were unaware of the treatment assignment 
until the 24- week follow- up visit.
Procedures
DMR was performed with the single catheter Revitasystem 
(Revita DMR(catheter and system), Fractyl Laboratories, 
Lexington, Massachusetts, USA) as previously described (online 
supplemental figure 2).16–18 A full DMR procedure was defined 
as five sequential ablations of 2 axial centimetres each, starting 
within 3 centimetres distal to the Ampulla of Vater towards the 
Ligament of Treitz, totalling 10 axial centimetres of circumferen-
tially ablated tissue in the duodenum during a single endoscopic 
session. The sham procedure consisted of placing the DMR cath-
eter over the guidewire into the stomach and leaving it in place 
for 30 min prior to removing it from the patient.
Study endpoints and assessments
The two primary efficacy endpoints were the absolute change 
from baseline at 24 weeks in HbA1c in all patients and abso-
lute change from baseline at 12 weeks in liver MRI proton 
density fat fraction (MRI- PDFF), specifically in those patients 
with NAFLD at baseline (liver MRI- PDFF >5%). The primary 
safety endpoints assessed were the incidence of device- related 
and procedure- related serious adverse events (SAEs), unantici-
pated adverse device events (UADEs), and AEs of special interest 
(AESIs), including hypoglycaemic events, through 24 weeks. 
Adverse events were recorded from the time the informed 
consent document was signed. The prespecified safety analysis 
tabulated the difference in the proportion of patients who expe-
rienced ≥1 major complication (DMR vs sham).
Secondary endpoints assessed were the relative change in liver 
MRI- PDFF from baseline at week 12 in patients with baseline 
liver MRI- PDFF >5% and absolute change from baseline at 
24 weeks in fasting plasma glucose (FPG) levels, weight, and 
homeostatic model assessment of IR (HOMA- IR).
Exploratory endpoints assessed were absolute change from 
baseline at 24 weeks in triglycerides, low- density lipoprotein 
cholesterol, high- density lipoprotein, alanine transaminase 
(ALT), and aspartate transaminase levels, and change in oral 
antidiabetic medication from baseline at week 24. In addition, 
the  percentage  of  patients  achieving  HbA1c  levels<53 mmol/
mol or liver fat content reduction >30% at the end of the study 
as well as the number of antihyperglycaemic drugs during the 
trial were assessed (see online supplemental table 2).
Rescue medications: persistent hyperglycaemia was a criterion 
to receive rescue medication, which was prescribed, per protocol 
(PP), with  increasing  doses  of  oral medications  and/or  insulin 
according to clinical practice guidelines (see online supplemental 
Summary box
What is already known about this subject?
 ► More than half of patients with type 2 diabetes mellitus 
are unable to sustain adequate glycaemic control with the 
current standard of care.
 ► Current approaches do not adequately target underlying 
disease pathophysiology (ie, insulin resistance (IR) and 
hyperinsulinaemia).
 ► Bariatric surgeries that bypass nutrient contact from the 
duodenum (eg, Roux- en- Y gastric bypass) improve glycaemic 
control and insulin sensitivity.
 ► Duodenal mucosal resurfacing is a minimally invasive, 
outpatient endoscopic procedure that targets duodenal 
pathology to treat insulin- resistance–related metabolic 
disease, including type 2 diabetes mellitus. Published data 
from earlier open- label studies have shown statistically 
significant improvements in haemoglobin A1c (HbA1c), 
alanine transaminase, aspartate transaminase, weight and 
homeostatic model assessment of IR through 12- month 
follow- up.
What are the new findings?
 ► In this first prospective, double- blind, sham- controlled study 
of Revita duodenal mucosal resurfacing, a single duodenal 
mucosal resurfacing procedure was well tolerated, safe, and 
elicits clinically and statistically significant improvements in 
HbA1c levels and liver fat content in European patients with 
poorly controlled type 2 diabetes mellitus.
 ► These results confirm that the duodenal mucosa is a 
therapeutic target for type 2 diabetes with or without non- 
alcoholic fatty liver disease/non- alcoholic steatohepatitis.
How might it impact on clinical practice in the foreseeable 
future?
 ► These data provide insight into a potential therapeutic 
opportunity for duodenal mucosal resurfacing to favourably 
impact both type 2 diabetes and non- alcoholic fatty liver 
disease/non- alcoholic steatohepatitis in a manner that can 
modify the natural history of these chronic and progressive 
diseases.
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table 3).19 20 Patients continued in the trial after receiving rescue 
medication.
Statistical analysis
The primary efficacy endpoints were planned to be tested for 
superiority of DMR versus  sham with adjustment  for multiple 
endpoints using the Hochberg procedure.21 Under this proce-
dure, DMR was considered beneficial over sham for both 
primary endpoints if the one- sided p value for each endpoint was 
<0.05;  and/or,  if  the one- sided  treatment  comparison p value 
was<0.025 for one endpoint, then DMR was considered benefi-
cial over sham for that given endpoint.
Intention-to-treat and PP analyses
The primary analysis population for primary and secondary 
endpoints was the modified intention- to- treat (mITT) popu-
lation, defined as all randomised patients in whom the study 
procedure was attempted and who had a baseline measurement 
for ≥1 primary endpoint. The PP population was defined as the 
subset of mITT patients who received the treatment to which 
they were randomised and strictly adhered to the protocol.
Safety analyses were completed in all patients in whom the 
treatment (DMR or sham) was initiated and included all AEs 
revealed during the follow- up, independent of duration. AEs 
and SAEs are presented as the number and percent of patients; 
overall counts were compared using the two- sided Clopper- 
Pearson 95% CI of the incidence rates.
The following additional analyses were conducted: (1) propor-
tion  of  all  patients who  achieved  an HbA1c  level <53 mmol/
mol at 24 weeks post procedure; (2) proportion of patients with 
baseline MRI- PDFF >5% who achieved a relative liver MRI- 
PDFF reduction >30% from baseline at week 12; (3) stratifica-
tion of end- study HbA1c by baseline FPG levels. The change in 
oral antidiabetic medication from baseline at week 24 (increase, 
neutral, or decrease) was assessed in patients with 24 weeks of 
follow- up.
Statistical analyses were performed using Statistical Analysis 
Software V.9.4 or later (SAS Institute) or R V.3.3.2 or later. 
See supplemental material for additional analyses details and 
powering assumptions.
Analysis of normality and homogeneity in the study populations
Assessments of normality and homogeneity were performed 
as specified in the statistical analysis plan. The normality tests 
assessed whether each variable was normally distributed. Assess-
ments of homogeneity evaluated consistency in treatment effect 
across geographic regions (Belgium, Brazil, Italy, Netherlands 
and UK) with a prespecified treatment- by- region interaction p 
value of<0.10 (see online supplemental methods for details).
An exploratory analysis using partial least- squares- discriminant 
analysis (PLS- DA) was performed to further understand and 
assess the interaction by regions in the prespecified study popu-
lations. PLS- DA is a useful exploratory analysis showing patterns 
related to a treatment effect without testing a formal hypoth-
esis; in other words, it provides a comparative and clear visual 
of different patterns in two samples (see online supplemental 
methods for details).
HOMA-IR and Matsuda Index Calculation





where G0 and I0 are premeal values for glucose and insulin and 
Gm and Im are mean post- meal values during the first 120 min 
of the liquid meal tolerance test with glucose and insulin values 
in mmol/L and mU/L, as validated for a meal test.23 24 Since the 
square root of the denominator takes into account the correc-
tion of nonlinear values distribution, these values are reported 
as mean±SD.
Role of the funding source
The funder of the study participated in study design, data collec-
tion, data analysis, data interpretation and writing of the report. 
The corresponding author (GM) had full access to all the data in 
the study and had final responsibility for the decision to submit 
the manuscript for publication.
Patient and public involvement
Patients were not directly involved in the design, recruitment or 
conduct of the study.
RESULTS
Patient baseline characteristics
Between 11 September 2017 and 15 December 2018, 359 
patients were screened and 250 were excluded from the study 
(figure 1). 109 patients were randomised (although one did 
not receive treatment due to oesophageal varices) 1:1 either to 
DMR (n=56) or to sham procedure (n=52); 75 in Europe (39 
DMR, 36 sham procedure) and 33 in Brazil (17 DMR, 16 sham 
procedure).
Overall, 71 patients (65.7%) were white, 7 (6.5%) were black, 
2 (1.8%) were Asian, 3 (2.8%) belonged to other races and 25 
(23.1%) preferred not to disclose their race.
Patient demographics and baseline characteristics were 
well balanced between the DMR and sham procedure groups 
(table 1). Men accounted for 69.4% of the patients. At baseline, 
the median body mass index was 31.5 (4.7) kg/m2 in the DMR 
group and 30.7 (5.7) kg/m2 in the sham group. The median base-
line HbA1c levels were 65.6 (8.7) mmol/mol in the DMR group 
and 66.1 (10.4) mmol/mol in the sham group. The median dura-
tion of diabetes was 10.0 (6.0) years and 9.1 (8.8) years among 
patients who underwent DMR or sham procedure, respectively. 
Most patients (85.5% in the DMR group and 82.7% in the 
sham group) had more than 5% fat accumulation in the liver as 
detected at baseline by MRI- PDFF.
mITT analysis and post-hoc analyses
In the overall mITT population (DMR n=56; sham n=52), the 





lute change in liver MRI- PDFF from baseline at 12 weeks was 
−5.4 (5.6)% in the DMR group compared with −2.9 (6.2)% in 
the sham group (p=0.096; treatment difference −2.5%).
A post- hoc analysis of pooled data from the overall PP popu-
lation stratified by baseline FPG levels demonstrated that in 
patients with FPG ≥10 mmol/L, the median (IQR) reduction in 
HbA1c at week 24 post procedure was –14.2 (17.5) mmol/mol 
post DMR compared with –4.4  (15.3) mmol/mol  in  the  sham 
group (p=0.002); whereas, in patients with FPG <10 mmol/L, 
the median reductions in HbA1c were similar between groups 
(p=0.148; figure 2A). In patients with baseline liver MRI- PDFF 
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>5% and  FPG  ≥10 mmol/L,  the  median  absolute  change  in 
liver MRI- PDFF was significantly greater in the DMR group 
compared with patients who underwent the sham procedure 
(p=0.001;  figure 2B). Similar results were observed in the 
European PP population for both HbA1c and liver fat content 
changes (figure 2C,D) and in the Brazilian PP population, but 
only for liver fat content (figure 2E,F).
PRIMARY AND SECONDARY ENDPOINTS BY REGION
Demographics and baseline characteristics were similar (table 1), 
but prespecified interaction testing by region showed heteroge-
neity between patients  in Europe  (DMR N=39;  sham N=36) 
and patients in Brazil (DMR N=17; sham N=16) for the HbA1c 
outcome (p=0.063). As such, European and Brazilian regions 
were analysed separately for all clinical outcomes. A post- hoc 
PLS- DA confirmed these regions were separate groups with 
different  variance/covariance  structures  (online  supplemental 
figure 3). The primary endpoints were found to be not normally 
distributed and are therefore presented as median (IQR).
PLS- DA is a linear classification model that is able to predict 
the class of new samples. We used PLS- DA as a post- hoc anal-
ysis that confirmed the European and Brazilian populations were 
separate  groups  with  different  variance/covariance  structures 
(figure 3). This analysis including all patients, regardless of treat-
ment group, showed that the first two components of PLS- DA 
explained 35% of the variance that contributed to the separation 
of the European and Brazilian populations. The general predic-
tive performance of the PLS- DA model in correctly classifying 
the patients as belonging to the European or to the Brazilian 
groups was very good as shown by the area under the curve of 
0.89. Therefore, due to heterogeneity demonstrated by multiple 
statistical methods and the unexpected differences seen between 
Europe and Brazil in the sham arms (table 2), analyses were strat-
ified by region.
In the European mITT population, the median change in 
HbA1c from baseline at 24 weeks post procedure was –6.6 
(17.5) mmol/mol in the DMR group compared with –3.3 (10.9) 
mmol/mol  in  the  sham procedure  group  (p=0.033;  treatment 
difference –3.3 mmol/mol; figure 3A). In patients with baseline 
liver MRI- PDFF >5%, the median absolute change in liver MRI- 
PDFF from baseline at 12 weeks revealed a reduction of liver 
fat content by 5.4 (6.1)% in the DMR group compared with 
2.2 (4.3)% in the sham procedure group (p=0.035; treatment 
difference –3.2%;  figure 3B). Similar results were observed in 
the European PP population and using a prespecified mixed- 
model repeated measures analysis (MMRM) (described within 
the online supplemental material).
In the Brazilian mITT population, change from baseline in 
HbA1c levels (figure 3C) was not significantly different in DMR 
compared with sham in the primary analysis, but was signifi-
cantly lower in the prespecified sensitivity MMRM analysis 
(p=0.104 and p=0.034, respectively). In Brazil, there was no 
significant difference between treatment groups in liver MRI- 
PDFF (figure 3D).
In the European mITT population, the median reduction in 
weight 24 weeks post procedure was significantly greater in 
the DMR group (–2.4 (2.8) kg) than in the sham group (–1.4 
(2.4) kg; p=0.012; treatment difference –1.0 kg; figure 4A). At 
12 weeks post procedure, European patients with baseline liver 
MRI- PDFF >5% had a significantly greater reduction of the 
median relative liver MRI- PDFF from baseline in the DMR group 
compared with the sham group (–32.1% (20.6%) vs –17.9% 
Figure 1 Patient disposition. Between 1 March 2017, and 15 December 2018, 109 of 359 patients assessed for eligibility were randomised. One 
patient at a European study site did not receive treatment due to oesophageal varicesa; therefore, the modified intention- to- treat (mITT) population 
included 108 patients—75 in Europe (39 to duodenal mucosal resurfacing (DMR) and 36 to sham) and 33 in Brazil (17 to DMR and 16 to sham). 
Prespecified assessments of normality and homogeneity (see the Methods section for details) revealed that the European and Brazilian populations 
were not poolable. Therefore, all efficacy analyses were stratified into two populations (Europe and Brazil). aThe one patient who withdrew and did 
not receive treatment was followed for safety, but not efficacy. Last completed visit was at week 4a, week 21 (phone call)b, and day 7 (phone call)d. 
PP, per protocol.
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Table 1 Baseline characteristics and demographics and change from baseline (modified intention- to- treat population*)
Parameter
Overall Europe† Brazil
DMR N=56 Sham N=52 P value DMR N=39
Sham
N=36 P value DMR N=17 Sham N=16 P value
Age, years 58.0 (13.5) 58.5 (14.0) 0.747 59.0 (13.0) 56.5 (14.0) 0.627 56.0 (13.0) 59.5 (11.5) 0.164
Sex, n (%) 0.963 0.93 0.866
  Female 17 (30.4) 16 (30.8) 9 (23.1) 8 (22.2) 8 (41.7) 8 (50.0)
  Male 39 (69.6) 36 (69.2) 30 (76.9) 28 (77.8) 9 (52.7) 8 (50.0)
Race, n (%) 0.974 0.658 0.562
  White 37 (66.1) 34 (65.4) 25 (64.1) 21 (58.3) 12 (70.6) 13 (81.3)
  Black 4 (7.1) 3 (5.8) 0 0 4 (23.5) 3 (18.8)
  Asian 1 (1.8) 1 (1.9) 0 1 (2.8) 1 (5.9) 0
  Other 1 (1.8) 2 (3.8) 1 (2.6) 2 (5.6) 0 0
  Undisclosed 13 (23.2) 12 (23.1) 13 (33.3) 12 (33.3) 0 0
Weight, kg
  Baseline 93.0 (15.9) 92.6 (26.4) 0.438 93.1 (16.5) 94.5 (24.6) 0.644 89.0 (15.6) 87.8 (19.8) 0.627
  Week 24 90.0 (17.5) 87.4 (26.0) 0.707 91.0 (17.5) 92.6 (27.0) 0.937 86.8 (19.7) 83.2 (22.6) 0.678
Change from baseline (week 24)
  Absolute −2.5 (4.5) −1.5 (3.3) 0.021 −2.4 (2.8) −1.4 (2.4) 0.012 −4.1 (5.6) −2.1 (5.7) 0.285
  Relative (%) −2.8 (4.5) −1.8 (3.5) 0.037 −2.6 (3.4) −1.5 (2.9) 0.013 −4.5 (5.7) −2.8 (5.6) 0.403
BMI, kg/m2
  Baseline 31.5 (4.7) 30.7 (5.7) 0.206 31.4 (4.5) 30.4 (6.1) 0.16 32.3 (4.7) 31.6 (6.2) 0.928
  Week 24 30.6 (5.2) 29.9 (5.5) 0.563 30.6 (5.0) 29.7 (6.3) 0.376 30.6 (5.6) 30.8 (5.9) 0.828
Change from baseline (week 24)
  Absolute −0.9 (1.5) −0.5 (1.1) 0.025 −0.8 (1.2) −0.5 (0.9) 0.011 −1.4 (1.9) −0.8 (1.9) 0.28
  Relative (%) −2.8 (4.5) −1.8 (3.5) 0.042 −2.6 (3.4) −1.5 (2.9) 0.013 −4.5 (5.7) −2.8 (5.6) 0.365
HbA1c levels, mmol/mol
  Baseline 65.6 (8.7) 66.1 (10.4) 0.839 65.0 (7.6) 66.1 (9.3) 0.45 70.5 (9.8) 65.6 (14.2) 0.213
  Week 24 55.2 (16.4) 61.2 (18.0) 0.436 59.6 (16.4) 63.9 (14.2) 0.132 51.9 (5.5) 48.6 (8.7) 0.104
Change from baseline (week 24)
  Absolute −10.4 (18.6) −7.1 (16.4) 0.147 −6.6 (17.5) −3.3 (10.9) 0.033 −20.2 (14.2) −17.5 (9.8) 0.104
  Relative (%) −16.7 (28.6) −10.6 (23.3) 0.184 −9.6 (27.1) −3.8 (18.3) 0.034 −27.6 (14.9) −25.6 (12.9) 0.105
DMR, duodenal mucosal resurfacing; HbA1c, haemoglobin A1c.
Figure 2 Post- hoc analysis of change in haemoglobin A1c (HbA1c) levels and liver MRI proton density fat fraction (MRI- PDFF) stratified by baseline 
fasting plasma glucose (FPG) level status (per- protocol (PP) populations). Median HbA1c per cent change from baseline to 24 weeks (duodenal 
mucosal resurfacing (DMR) versus sham procedure) in the overall (A), European (C) and Brazilian (E) PP patients with baseline FPG ≥10 mmol/L 
compared with patients with baseline FPG <10 mmol/L. In patients with baseline liver MRI- PDFF >5%, median liver MRI- PDFF per cent change from 
baseline to 12 weeks (DMR vs sham procedure) in the overall (B), European (D), and Brazilian (F) PP patients with baseline FPG ≥10 mmol/L compared 
with FPG <10 mmol/L. Treatment comparison of one- sided p value based on analysis of covariance model with multiple imputation on the rank values 
(modified ridit scores). Via multiple imputation, analysis is based on all patients in the population of interest. The overall PP population includes 
patients from both European and Brazilian study sites. The European PP population consists of patients from Italy, UK, Belgium and Netherlands.
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(25.6%);  p=0.020;  treatment  difference  –14.2%;  figure 4B). 
Median reduction in FPG levels from baseline at 24 weeks post 
procedure was numerically lower in the DMR group compared 
with  sham  procedure  group  (–1.5 mmol/L  (4.6 mmol/L)  vs 
–0.9 mmol/L  (3.0 mmol/L);  p=0.217;  treatment  difference 
–0.6 mmol/L;  figure 4C), and median reduction in HOMA- IR 
was numerically lower in the DMR group compared with the 
sham group (–1.3 (2.5) vs –0.4 (1.5); p=0.060; treatment differ-
ence –0.9; figure 4D). Sensitivity analysis of HOMA- IR reached 
statistical significance in non- imputed complete case analysis 
for missing secondary endpoint data (p=0.028), indicating an 
insulin- sensitising mechanism of DMR. The mean (SD) increase 
in Matsuda Index, a post- hoc analysis of insulin sensitivity 
(higher numbers denoting better insulin sensitivity), was greater 
in the DMR group compared with the sham group (1.2±2.7 vs 
0.2±1.5; p=0.035; treatment difference 1.0).
The mITT analysis of the relative changes in weight, liver fat 
content (MRI- PDFF), FPG and HOMA- IR in the Brazilian popu-
lation did not show any significant difference between DMR and 
sham groups (figure 4E–H, respectively).
In the European mITT population, the DMR group had 
significantly  more  patients  achieving  HbA1c  levels<53 mmol/
mol at 24 weeks compared with the sham group (26.3% vs 
9.1%; p=0.031; online supplemental figure 4A). Similarly, 53% 
of patients in the DMR group with baseline MRI- PDFF >5% 
achieved a relative liver MRI- PDFF reduction >30% from base-
line at week 12, compared with 22% in the sham procedure 
group (p=0.008; online supplemental figure 4B).
Finally, most patients experienced no change or had an 
increased use in oral antidiabetic medication from baseline at 
week 24 in both the European and Brazilian mITT populations 
(online supplemental table 4).
TIME OF PROCEDURE
The median total catheter indwelling time in the entire sample 
was 56∙.0 min (26∙.0 min).
SAFETY ANALYSIS
All patients were included in the safety analysis, 76 in Europe 
(DMR n=39; sham n=37) and 33 in Brazil (DMR n=17; sham 
n=16). Most AEs were mild and  transient;  the most common 
Figure 3 Haemoglobin A1c (HbA1c) levels and liver MRI proton density fat fraction (MRI- PDFF) at 24 weeks post duodenal mucosal resurfacing 
(DMR) (primary endpoint). Median per cent change in HbA1c levels (DMR vs sham procedure) from baseline to 24 weeks in the European (A) and 
Brazilian (B) modified intention- to- treat (mITT) and per- protocol (PP) populations. Median absolute per cent change in liver MRI- PDFF (DMR vs sham 
procedure) from baseline to 24 weeks in patients with baseline MRI- PDFF >5% (*) in the European (C) and Brazilian (D) mITT and PP populations. 
Treatment comparison one- sided p value based on analysis of covariance model with multiple imputation on the rank values (modified ridit scores). 
Via multiple imputation, analysis is based on all patients in the population of interest where post rescue values are first set to missing. Data for 
continuous variables are on non- imputed unadjusted descriptive statistics based on patients with non- missing values.
Table 2 Change from baseline in haemoglobin A1c (HbA1c) levels, 
liver MRI proton density fat fraction (MRI- PDFF) and weight (sham- 






HbA1c levels at 24 weeks, mmol/mol n=33 n=15
−3.3 (10.9) −17.5 (9.8)
Liver MRI- PDFF >5% at baseline, n (%) 28 (75.7) 14 (87.5)
Absolute change in liver MRI- PDFF at 12 weeks, % −2.2 (4.3) −6.1 (7.8)
Weight at 24 weeks, kg n=34 n=15
−1.4 (2.4) −2.1 (5.7)
Data are presented as median (IQR), unless otherwise indicated.
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Figure 4 Clinically meaningful reductions in weight, liver fat and homeostatic model assessment of insulin resistance (HOMA- IR) with duodenal 
mucosal resurfacing (DMR). Median weight (kg) change from baseline to 24 weeks (DMR vs sham procedure) in the European (A) and Brazilian (B) 
modified intention- to- treat (mITT) and per- protocol (PP) populations. Median relative liver MRI proton density fat fraction (MRI- PDFF) per cent change 
from baseline to 12 weeks in patients with baseline MRI- PDFF >5% (*) in the European (C) and Brazilian (D) mITT and PP populations. Median fasting 
plasma glucose (FPG; millimoles per litre) change from baseline to 24 weeks (DMR vs sham procedure) in the European (E) and Brazilian (F) mITT and 
PP populations. Median HOMA- IR change from baseline to 12 weeks (DMR vs sham procedure) in the European (G) and Brazilian (H) mITT and PP 
populations. Data for continuous variables are on non- imputed unadjusted descriptive statistics based on patients with non- missing values. Treatment 
comparison one- sided p value based on analysis of covariance model on ranks (modified ridit scores) where post rescue values are first set to missing. 
Last rank carried forward on ranks was used for missing data for FPG levels, weight and HOMA- IR endpoints. HOMA- IR was determined as (FPG * 
fasting insulin)/135, where FPG levels were measured in millimoles per litre and fasting insulin is measured in picomoles per litre.
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were abdominal pain, diarrhoea, hyperglycaemia, hypogly-
caemia, nasopharyngitis and headache. In the European popu-
lation, no device- related or procedure- related SAEs or UADEs 
were reported through 24 weeks post procedure (table 3). 
Approximately 33% of patients in the DMR group (n=13) expe-
rienced a device- related or procedure- related AESI, compared 
with 27% of patients (n=10) in the sham procedure group. The 
most common (occurring in ≥5% of patients) device- related or 
procedure- related  AESIs  occurring  ≤30  days  post  procedure 
were abdominal pain and hypoglycaemia. Similar number of 
events and percentage of patients with events of hypoglycaemia 
(related to procedure) were found in both groups (4 events; 7.7% 
(3/39) patients with event in DMR group and 8 events; 10.8% 
(4/37 patients with  events  in  the  sham group)). There was  an 
absence of pancreatitis, infection and thermal injury. Follow- up 
endoscopy  was  performed  (n=32);  overall,  the  duodenum 
appeared normal with complete healing.
In the Brazilian population, 11.8% of patients (n=2) in 
the DMR group experienced SAEs related to the procedure 
(table 3). One SAE was a precautionary hospitalisation for eval-
uation for a patient who noted mild haematochezia 8 days after 
a DMR procedure. The haematochezia was ascribed to a visible 
external haemorrhoid; however, the investigator adjudicated it 
as possibly  related  to procedure. The other SAE was  a  jejunal 
perforation caused by manipulation of the endoscope used in 
the procedure during the performance of an upper endoscopy, 
requiring surgical repair with no further sequelae. Hypogly-
caemia  (related  to  procedure) was  reported  in  47%  (8/17)  of 
patients in the DMR group and 56% (n=9/16) in the sham group 
with 64 and 74 events in each arm, DMR versus sham, respec-
tively. Follow- up endoscopy was performed (n=17); overall, the 
duodenum appeared normal with complete healing.
DISCUSSION
In REVITA-2, a randomised, double- blind, sham- controlled, 
multicentre trial in patients with poorly controlled T2D with 
or without NAFLD, a single DMR procedure was well toler-
ated. Due to the regional heterogeneity revealed by interaction 
testing, the European and Brazilian populations were analysed 
separately. Though there was less power to detect a statistical 
difference between DMR and sham arms, in the European popu-
lation DMR elicited a greater improvement than sham proce-
dure in both primary endpoints (HbA1c and liver fat content via 
MRI- PDFF), as well as in secondary measures of insulin sensi-
tivity and body weight. Significant differences in weight loss, 
HbA1c and hypoglycaemic events were found between the two 
European and Brazilian populations after unblinding, including 
in the sham arms. The fact that HbA1c in the sham group was 
reduced by 3.3 mmol/mol  in  the European population  (consis-
tent with prestudy assumptions), but by 17.5 mmol/mol  in  the 
Brazilian population (much greater than prestudy assumptions 
or even the magnitude of benefit from more potent anti- diabetic 
drugs) suggest these patients had a more intensive approach in 
their treatment of diabetes on study enrolment than the Euro-
pean ones, which led to the clinical and statistical differences 
observed between these populations. This is also true for dieting, 
since the weight loss was almost double in the Brazilian popu-
lation as compared with the European population, which may 
explain the differences in observed treatment effect on MRI- 
PDFF in the European versus Brazilian populations. Despite the 
large sham effect size and smaller sample size, Brazilian patients 
treated with DMR also trended towards evidence of glycaemic 
efficacy. In Brazil, improvements in HbA1c levels compared with 
sham- treated patients were not significant in the primary statis-
tical analysis of the cohort but were statistically significant on the 
mixed- model repeated measures sensitivity analyses.
Overall, we can affirm that in patients with marked hepatic 
IR (FPG ≥10 mmol/L and who represent up to 65% of patients 
with T2D),25 DMR demonstrates meaningful improvements 
in both HbA1c and liver MRI- PDFF compared with the sham 
procedure. The post- hoc results in the overall population strat-
ified by baseline FPG ≥10 mmol/L or <10 mmol/L are remark-
able due to the magnitude of the effect size relative to sham in 
the high baseline FPG population: difference of –9.8 mmol/mol 
(3.0%) in HbA1c and –4.5% liver fat content between DMR 
and sham. This striking difference was also seen in the Euro-
pean population with high baseline FPG, with HbA1c reduction 
of  −13.1 mmol/mol  in  DMR  versus  −1.6 mmol/mol  in  sham 
(p=0.005)  at  24 weeks  and MRI- PDFF  reductions  of −8.0% 
vs −2.1% (p=0.006) at 12 weeks. Consistent with this, DMR 
Table 3 Device- related/procedure- related adverse events through 24 weeks post procedure (safety population)
Europe Brazil
DMR N=39 Sham N=37 DMR N=17 Sham N=16
# of 
events n (%) 95% CI‡
# of 
events n (%) 95% CI‡ # of events n (%) 95% CI‡ # of events n (%) 95% CI‡
Summary (through 24 weeks post- treatment)
  SAE 0 0 (0.0 to 9.0) 0 0 (0.0 to 9.5) 3 2 (11.8) (1.5 to 36.4) 0 0 (0.0 to 20.6)
  UADE 0 0 (0.0 to 9.0) 0 0 (0.0 to 9.5) 0 0 (0∙0 to 19.5) 0 0 (0.0 to 20.6)
  AESI 19 13 (33.3) (19.1 to 50.2) 16 10 (27.0) (13.8 to 44.1) 74 12 (70.6) (44.0 to 89.7) 76 10 (62.5) (35.4 to 84.8)
Most common (≥5%) AESIs by preferred term (≤30 days post- treatment)
  Abdominal pain 9 7 (17.9) (7.5 to 33.5) 2 2 (5.4) (0.7 to 18.2) 6 5 (29.4) (10.3 to 56.0) 2 2 (12.5) (1.6 to 38.4)
  Diarrhoea 1 1 (2.6) (0.1 to 13.5) 2 2 (5.4) (0.7 to 18.2) 1 1 (5.9) (0.2 to 28.7) 1 1 (6.3) (0.2 to 30.2)
  Nausea 1 1 (2.6) (0.1 to 13.5) 0 0 (0.0 to 9.5) 2 2 (11.8) (1.5 to 36.4) 0 0 (0∙0 to 20∙6)
  Vomiting 1 1 (2.6) (0.1 to 13.5) 0 0 (0.0 to 9.5) 1 1 (5.9) (0.2 to 28.7) 0 0 (0∙0 to 20∙6)
  Hypoglycaemia 3 3 (7.7) (1.62 to 20.9) 3 2 (5.4) (0.7 to 18.2) 11 6 (35.3) (14.2 to 61.7) 21 7 (43.8) (19.8 to 70.1)
Most common (≥5%) AESIs by preferred term (>30 days post- treatment)
  Abdominal pain 1 1 (2.6) (0.1 to 13.5) 2 2 (5∙4) (0.7 to 18.2) 0 0 (0.0 to 19.5) 0 0 (0.0 to 20.6)
  Hypoglycaemia 1 1 (2.6) (0.1 to 13.5) 4 2 (5∙4) (0.7 to 18.2) 53 5 (29.4) (10.3 to 56.0) 52 8 (50.0) (24.7 to 75.4)
Data are presented as n (%), with n as the number of patients with an event.
*The primary safety analysis population was defined as all patients in whom the treatment (DMR or sham) was initiated.
†European safety population included patients from Italy, UK, Belgium and Netherlands.
‡Two- sided Clopper- Pearson 95% CI of the incidence rates.
AESI, adverse event of special interest; DMR, duodenal mucosal resurfacing; SAE, serious adverse event; UADE, unanticipated adverse device effect.
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demonstrated statistically significant benefits on markers of IR 
in the European population, including HOMA- IR and Matsuda 
Index. Future studies enriching for patients with greater degrees 
of IR, such as high- baseline FPG patients, may result in a more- 
pronounced treatment effect of DMR on glycaemic and hepatic 
parameters.
Unlike for T2D, there are no proven pharmacological ther-
apies available to treat patients with NAFLD. Meanwhile, the 
downstream consequences of NAFLD are now becoming more 
apparent with accelerated incidence rates of non- alcoholic steato-
hepatitis (NASH), cirrhosis, liver transplant and hepatocellular 
carcinoma being reported in patients with T2D.26 27 We wanted 
to understand the extent of fatty liver in our patient popula-
tion at baseline and throughout the study, therefore performed 
MRI- PDFF on patients at baseline and at week 12. Although 
the REVITA-2 study did not require a NAFLD diagnosis in 
patients at baseline, approximately 85% of patients had fatty 
liver, confirming prior evidence of the growing epidemiological 
overlap with T2D. Altogether, the prevalence of fatty liver in the 
overall REVITA-2 study population supports the concept and 
emphasises further the need for a call for action to implement 
effective screening programmes and methods to detect presymp-
tomatic  stages  of NAFLD/NASH  and  liver  fibrosis  in  patients 
with T2D. This approach could completely change the paradigm 
of how the epidemic of NAFLD/NASH is addressed today.28 In 
REVITA-2, patients with NAFLD (liver MRI- PDFF >5%)29 at 
baseline in the European cohort or in those patients with FPG 
≥10 mmol/L  showed a  large magnitude and a clinically mean-
ingful reduction in liver fat content at week 12, confirming 
earlier findings of non- invasive measurements (including reduc-
tions in ALT levels through 2 years).24–26 Additionally, the Euro-
pean cohort has statistically significant differences between the 
DMR and sham arms with regards to the number of patients 
that had a decline of 30% or more in MRI- PDFF from baseline 
at week 12. Emerging data over the recent years have suggested 
that a 30% relative reduction in liver fat content as assessed by 
MRI- PDFF may be associated with histological improvement in 
NASH. Most recently, a multicentre study validated this associa-
tion.30 Liver biopsies were not performed in REVITA-2 as it was 
not our objective to confirm NASH in our patient population. 
These data provide insight into a potential therapeutic oppor-
tunity for DMR, at least in a selected population, to favourably 
treat both T2D and NAFLD/NASH in a manner that can modify 
the natural history of these chronic and progressive diseases.
Results from REVITA-2 confirm that DMR has a favourable 
safety profile. No UADEs were reported through 24 weeks post 
treatment, and there were no clinical or laboratory signs of AEs 
related to malabsorption, anaemia, pancreatitis, biliary compli-
cations or infection. Two SAEs were seen in the Brazilian safety 
population. During the study, a significantly larger number of 
asymptomatic events of hypoglycaemia were observed in Brazil 
than in Europe. After unmasking, it became clear that this is most 
likely due to the overall lower levels of ambient glycaemia in the 
Brazilian population relative to the European patients and also 
raises important considerations of the use of DMR in conjunc-
tion with antihyperglycaemic agents that have a known risk of 
causing hypoglycaemia (ie, sulfonylureas). Further assessment of 
the long- term (48 week) safety and efficacy of DMR is underway.
Limitations of this feasibility study include the relatively small 
patient population and heterogeneity between European and 
Brazilian populations. Moreover, the trial was not stratified for 
baseline characteristics relative to the secondary outcomes; there-
fore, differences in baseline insulin concentrations, length of 
time with T2D and number of baseline medications were found, 
and this may be contributing to differences in outcomes. Next, 
while full type-1 error was incorporated for the two primary 
endpoints, we acknowledge that there is a lack of control for 
false discovery rate in this study for our secondary and explor-
atory endpoints;  therefore,  those  results  should be  interpreted 
with appropriate context. In relation to the differences in statis-
tical and clinical results seen between the European and Brazilian 
populations, it is important to acknowledge that adherence to 
previously  prescribed  medications  could  not  be  objectively 
assessed in this study and race was not collected in the majority 
of the patient population in Europe. In a follow- up study, it 
will also be important to confirm the MRI- PDFF results with 
additional non- invasive tests such as fibroscan to evaluate Revita 
DMR’s potential to additionally improve liver fibrosis. Lastly, 
this short- term study concluded at 48 weeks. Follow- up data on 
the 48 week DMR results are forthcoming, as well as plans for 
a pivotal study (Revita T2Di; NCT04419779)  in T2D insulin- 
treated patients. This will be important research to confirm the 
metabolic benefits seen thus far in patients with T2D with or 
without NAFLD, provide long- term follow- up (including biop-
sies of the duodenal mucosa to further understand the long- term 
morphological changes), and provide the opportunity to under-
stand the biological mechanisms likely behind the benefit of 
DMR on the treatment of these pathological conditions.
In conclusion, DMR is a safe procedure that significantly 
improved glycaemic control and reduced liver fat content in the 
European population compared with the sham procedure. In 
addition, a post- hoc analysis in the overall population showed 
that patients with high baseline FPG  levels  (≥10 mmol/L) had 
significantly greater reductions in HbA1c post- DMR, versus 
sham.
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